The European Commission has granted Fresenius Kabi marketing authorisation for Stimufend, a pegfilgrastim biosimilar, for all indications of the reference product. Stimufend stimulates the growth of certain white blood cells, which are essential for preventing or fighting infections, which is often a life-threatening risk in patients receiving myelosuppressive chemotherapy. It is the first biosimilar molecule approved for cancer therapy and the second biosimilar approved in Europe in Fresenius Kabi's portfolio. The company is thus expanding its product range focused on autoimmune diseases and oncology.

Contact:

Fresenius SE & Co. KGaA

Else-Kroner-Str. 1

61352 Bad Homburg v.d.H.

Germany

T: +49 (0) 6172 608-0

E: pr-fre@fresenius.com

(C) 2022 Electronic News Publishing, source ENP Newswire